Auris Medical Announces Formation of Scientific Advisory Board for Tinnitus Programs
August 26 2019 - 9:00AM
Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company
dedicated to developing therapeutics that address important unmet
medical needs in neurotology and central nervous system disorders,
today announced the formation of a Scientific Advisory Board (SAB)
for its tinnitus research and development programs.
“We are delighted to have several world-renowned
tinnitus experts join Auris Medical as advisors as we are preparing
to advance our various tinnitus projects through further clinical
and pre-clinical development,” stated Thomas Meyer, Auris Medical’s
founder, Chairman and CEO. “There continues to be a strong unmet
medical need amongst tinnitus sufferers worldwide, and we look
forward to bringing novel therapeutics to patients. Thanks to the
support from our new Scientific Advisory Board and the learnings
from our late-stage trials with Keyzilen®, we feel that we are in a
good position to take Keyzilen® as well as our early-stage projects
forward.”
The appointments to Auris Medical’s Tinnitus SAB
include:
- Wolfgang Arnold, Professor Emeritus, former Director of the
Department of Otolaryngology, Head and Neck Surgery of the
Technical University of Munich, Germany
- David Baguley, PhD, MBA, Professor in Hearing Sciences, Faculty
of Medicine & Health Sciences, University of Nottingham,
UK
- Richard Salvi, SUNY Distinguished Professor and Director for
the Center for Hearing and Deafness at the University at Buffalo,
NY
- Hinrich Staecker, MD, PhD, Professor, Director Division
Otology/Neurotology, University of Kansas, KS
The Company aims to implement the further
development of Keyzilen® as well as its early-stage tinnitus
programs with non-dilutive funding.
About Auris Medical
Auris Medical is a biopharmaceutical company
dedicated to developing therapeutics that address important unmet
medical needs in neurotology and central nervous system disorders.
The company is focused on the development of intranasal betahistine
for the treatment of vertigo (AM-125) and for the treatment of
antipsychotic-induced weight gain and somnolence (AM-201). These
projects have gone through two Phase 1 trials and entered into
proof-of-concept studies in 2019. In addition Auris Medical has two
Phase 3 programs under development: Sonsuvi® (AM-111) for acute
inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear
tinnitus. The Company was founded in 2003 and is headquartered in
Hamilton, Bermuda. The shares of Auris Medical Holding Ltd. trade
on the NASDAQ Capital Market under the symbol “EARS.”
Forward-looking Statements
This press release may contain statements that
constitute “forward-looking statements” within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Forward-looking statements are
statements other than historical facts and may include statements
that address future operating, financial or business performance or
Auris Medical’s strategies or expectations. In some cases, you can
identify these statements by forward-looking words such as “may,”
“might,” “will,” “should,” “expects,” “plans,” “anticipates,”
“believes,” “estimates,” “predicts,” “projects,” “potential,”
“outlook” or “continue,” or the negative of these terms and other
comparable terminology. Forward-looking statements are based on
management’s current expectations and beliefs and involve
significant risks and uncertainties that could cause actual
results, developments and business decisions to differ materially
from those contemplated by these statements. These risks and
uncertainties include, but are not limited to, Auris Medical’s need
for and ability to raise substantial additional funding to continue
the development of its product candidates, the timing and conduct
of clinical trials of Auris Medical’s product candidates and that
such trials will not meet their endpoints , the clinical utility of
Auris Medical’s product candidates, the timing or likelihood of
regulatory filings and approvals, Auris Medical’s intellectual
property position and Auris Medical’s financial position, including
the impact of any future acquisitions, dispositions, partnerships,
license transactions or changes to Auris Medical’s capital
structure, including future securities offerings. These risks and
uncertainties also include, but are not limited to, those described
under the caption “Risk Factors” in Auris Medical’s Annual Report
on Form 20-F for the year ended December 31, 2018 and future
filings with the Securities and Exchange Commission.
Forward-looking statements speak only as of the date they are made,
and Auris Medical does not undertake any obligation to update them
in light of new information, future developments or otherwise,
except as may be required under applicable law. All forward-looking
statements are qualified in their entirety by this cautionary
statement.
Investor contact: Joseph Green Edison Advisors
for Auris Medical 646-653-7030 jgreen@edisongroup.com
Or
investors@aurismedical.com
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Sep 2023 to Sep 2024